Mesothelioma is a cancer that forms in the thin tissue lining surrounding the body’s internal organs, called the mesothelium. It is caused almost exclusively by asbestos exposure. Understanding which type of mesothelioma a patient has determines the available treatment options, the specialists needed, the prognosis, and the legal claims that may apply. There are four main types classified by location and three cell types that further define the disease.
At The Williams Law Firm, P.C., Attorney Joseph P. Williams has represented patients with every type of mesothelioma for more than 30 years and has never lost a mesothelioma case. If you or a loved one has received any mesothelioma diagnosis, you may be entitled to significant compensation.
⚠ Time-Sensitive — New York Law Limits Your Window to File
Diagnosed with mesothelioma in New York? The 3-year statute of limitations runs from your diagnosis date, not your exposure date.
Over 1,000 families represented. Hundreds of millions recovered. Never lost a mesothelioma case. No fees unless we win.
| Type | Location | % of Cases | Median Survival |
|---|---|---|---|
| Pleural | Lining of the lungs | 80–90% | ~18 months with treatment |
| Peritoneal | Lining of the abdomen | 10–15% | 2.5 years; 5+ years with HIPEC |
| Pericardial | Lining of the heart | <1% | ~6 months; improving with multimodal treatment |
| Testicular | Lining of the testes | <1% | ~6 years with treatment |
Pleural mesothelioma forms in the pleura, the two-layer membrane surrounding the lungs and lining the chest wall. It is the most common form, accounting for 80 to 90 percent of all cases. When asbestos fibers are inhaled, they can travel to the pleural space where they cause chronic inflammation and eventually trigger tumor growth. The tumors typically begin as small nodules on the pleural surfaces and progress to a tumor rind enveloping the lung.
Early symptoms include chest pain on one side, persistent dry cough, and shortness of breath. Pleural effusion — fluid buildup between the lung and chest wall — causes increasingly severe breathlessness as the disease advances. Constitutional symptoms including unexplained weight loss, fatigue, and night sweats appear with progression. Treatment options include pleurectomy/decortication (P/D) surgery, chemotherapy with pemetrexed and cisplatin, and the FDA-approved nivolumab plus ipilimumab immunotherapy for unresectable cases. Median survival with current multimodal treatment is approximately 18 months; early-stage patients treated with surgery plus systemic therapy may achieve 3 years or more.
Peritoneal mesothelioma forms in the peritoneum, the membrane lining the abdominal cavity and its organs. It accounts for 10 to 15 percent of cases. Asbestos fibers that are ingested rather than inhaled can migrate to the peritoneum, which is why peritoneal mesothelioma includes more women and more patients without heavy occupational exposure histories than pleural mesothelioma.
Symptoms include abdominal pain, bloating, a feeling of fullness, nausea, and ascites (abdominal fluid causing progressive swelling). Peritoneal mesothelioma is frequently misdiagnosed as ovarian cancer in women or peritoneal carcinomatosis from a gastrointestinal primary. The most effective treatment is cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC), which delivers chemotherapy directly into the abdominal cavity at the time of surgery. Patients who qualify for CRS/HIPEC at specialized centers have median survival times of 2.5 to over 7 years, with some long-term survivors exceeding a decade.
Pericardial mesothelioma forms in the pericardium, the sac surrounding the heart. It accounts for less than 1 percent of all mesothelioma cases and fewer than 200 cases have been documented in the medical literature. Symptoms — chest pain, palpitations, breathlessness, and fatigue — resemble cardiac conditions, making diagnosis difficult. Pericardial effusion causing cardiac tamponade is a defining feature of advanced disease. Pericardiectomy (surgical removal of the pericardium) is the primary intervention where feasible, with chemotherapy and radiation used in palliative settings.
Testicular mesothelioma forms in the tunica vaginalis, the membrane covering the testes. It is the rarest form, accounting for less than 1 percent of cases. Symptoms include scrotal swelling, hydrocele (fluid in the scrotum), and a palpable scrotal mass often mistaken for a hernia or cyst. It has the best prognosis of any mesothelioma type, with a median survival of approximately six years. Primary treatment is orchiectomy (surgical removal of the affected testicle and spermatic cord), followed by chemotherapy or radiation in some cases.
Beyond location, mesothelioma is classified by cell type — the microscopic appearance of the tumor cells — which profoundly affects prognosis and treatment response.
Epithelioid cells are uniform and well-organized under microscopy. They grow more slowly, are more responsive to chemotherapy and immunotherapy, and are associated with the best prognosis of the three cell types. Patients with epithelioid mesothelioma are most likely to qualify for surgical treatment.
Sarcomatoid mesothelioma has elongated, irregular cells that grow rapidly and spread quickly. It is the most aggressive cell type, least responsive to standard chemotherapy, and patients are often not surgical candidates. Recent data suggest immunotherapy may offer better responses than chemotherapy for sarcomatoid tumors in some patients.
Biphasic mesothelioma contains both epithelioid and sarcomatoid components. Prognosis and treatment response depend on the ratio of the two cell types. Accurate cell type quantification requires experienced pathology review of adequate tissue samples and may require a second opinion from a specialist center.
Treatment is most effective when delivered by a multidisciplinary team at a center with significant mesothelioma experience. Core treatments across types include surgery for eligible patients, chemotherapy with pemetrexed and cisplatin, immunotherapy (nivolumab plus ipilimumab for unresectable pleural mesothelioma, increasingly applied across types), and radiation for targeted symptom control. Peritoneal patients who qualify for CRS/HIPEC have the best outcomes of any mesothelioma subtype in the current treatment landscape. Clinical trials at major mesothelioma centers offer access to cutting-edge treatments not available in community oncology settings.
Every type of mesothelioma — pleural, peritoneal, pericardial, or testicular — can give rise to legal claims against the parties responsible for the asbestos exposure that caused it. The manufacturers of asbestos-containing products, employers who exposed workers to asbestos, and property owners who failed to manage asbestos safely may all bear legal responsibility. More than 60 asbestos bankruptcy trust funds hold billions of dollars available to compensate victims regardless of mesothelioma type.
In New York, the statute of limitations for a personal injury claim is three years from the date of diagnosis. In New Jersey it is two years. Contact The Williams Law Firm, P.C. through our contact form to schedule a free consultation with our mesothelioma lawyers. You pay nothing unless we win.
Pleural mesothelioma, which forms in the lining around the lungs, accounts for 80 to 90 percent of all mesothelioma diagnoses. Peritoneal mesothelioma (abdominal lining) is second at 10 to 15 percent. Pericardial and testicular mesothelioma each account for less than 1 percent of cases. The predominance of pleural mesothelioma reflects the primary route of asbestos exposure — inhalation — which delivers fibers directly to the pleural space.
Testicular mesothelioma has the best median survival (approximately six years) due to its localized nature and surgical effectiveness. Among the more common types, peritoneal mesothelioma in patients who qualify for CRS/HIPEC has dramatically improved outcomes, with some patients achieving five-year survival rates above 50 percent and some long-term survivors living a decade or more. Pleural mesothelioma has a median survival of approximately 18 months with current treatment. Pericardial mesothelioma has the worst overall prognosis at approximately six months, though multimodal treatment is improving outcomes.
These terms refer to the cell type of the tumor. Epithelioid (70% of cases) is the most common, slowest-growing, and most responsive to treatment. Sarcomatoid (10%) is the rarest, most aggressive, and least responsive to standard chemotherapy. Biphasic (20%) contains both cell types, with prognosis depending on the relative proportions. Cell type is determined by pathological analysis of a biopsy sample and is a critical factor in treatment planning and surgical eligibility.
Yes, though it is uncommon. Mesothelioma typically presents in one primary location, but it can spread to involve adjacent mesothelial surfaces over time. Some patients develop both pleural and peritoneal involvement, particularly as the disease advances. Concurrent primary involvement of multiple sites at initial presentation is rare. When multiple sites are involved, treatment becomes more complex and typically focuses on systemic therapy (chemotherapy or immunotherapy) rather than site-specific surgery.
Asbestos exposure is the primary cause of all mesothelioma types, with the relationship strongest for pleural mesothelioma. Peritoneal mesothelioma is also strongly linked to asbestos, particularly through ingested fibers. Pericardial and testicular mesothelioma are so rare that definitive causal data are limited, and some cases appear to occur without documented asbestos exposure. Radiation exposure to the chest has been documented as a secondary risk factor in rare cases.
Get a copy of our FREE mesothelioma e-book by attorney Joseph Williams
